Results 281 to 290 of about 257,826 (338)

Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis. [PDF]

Syst Rev
Huang X, Zhou J, Qian Y, He J, Yang L, Wang Z, Wei D, Li M, Ma W, Lang H.   +9 more
europepmc   +1 more source

The Time Lag Associated With the Reclassification of Germline BRCA Variants' Pathogenicity Is Critical for Cancer Patients

Cancer Science, EarlyView.
The period for reclassifying the variants' pathogenicity is too long for patients with advanced or recurrent cancers with variants of uncertain significance that can be objectively re‐evaluated to be (likely) pathogenic according to accumulated evidence.
Tomomi Hayashi, Hiroyuki Matsubayashi, Yoshimi Kiyozumi   +2 more
wiley   +1 more source

Molecular insight into the role of benzotriazole nanocapsule to deliver anticancer drug in smart drug delivery system. [PDF]

Sci Rep
Sajjad A, Sarfaraz S, Abdul Hamid MHS, Keasberry NA, Lakhani A, Sheikh NS, Ayub K.   +6 more
europepmc   +1 more source

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma

Cancer Science, EarlyView.
CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara, Isao Yoshida, Takuro Ishiguro, Katsuya Fujimoto, Junya Kuroda, Toshiki Uchida, Ryusuke Yamamoto, Yoshiaki Ogawa, Yasushi Hiramatsu, Toshiro Ito, Seiichiro Katagiri, Tomonori Nakazato, Kazumi Suzukawa, Kenzo Kinami, Mi Zhou, Eiju Negoro   +15 more
wiley   +1 more source

Corrigendum to Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial. [PDF]

Chin J Cancer Res
europepmc   +1 more source

Hydrogen sulfide and ferroptosis inhibition underlies the dietary restriction-induced protection against cyclophosphamide cystitis. [PDF]

Front Pharmacol
Mao Z, Chen P, Ji Q, Zhao X, Zhong K, Zeng X.   +5 more
europepmc   +1 more source

Evans Blue Acts as a Selective Inhibitor of CaMKII‐α to Impede the Progression of TCL Identified by HTS

Cancer Science, EarlyView.
ABSTRACT T‐cell lymphoma (TCL) poses a significant challenge in clinical oncology, characterized by its aggressive behavior and resistance to conventional therapies. Despite considerable research efforts, the prognosis for TCL patients remains poor, primarily due to the lack of effective therapeutic strategies that can inhibit tumor progression and ...
Jianru Tian, Aiqin Zhang, Lansong Li, Hong Liu, Hui Jiang, Ruqi Liang   +5 more
wiley   +1 more source

Personalizing neoadjuvant chemotherapy regimens for triple-negative breast cancer using a biology-based digital twin. [PDF]

NPJ Syst Biol Appl
Christenson C, Wu C, Hormuth DA, Ma J, Yam C, Rauch GM, Yankeelov TE.   +6 more
europepmc   +1 more source

Mechanistic Insights and Therapeutic Potentials of Ubiquitin‐Proteasome System in Non‐Small Cell Lung Cancer

Cell Proliferation, EarlyView.
Lung cancer development involves mechanisms like reduced EGFR/EGF ubiquitination driving cancer cell behaviors and immune evasion via loss of PD‐1/PD‐L1 ubiquitination. Balancing ubiquitination and deubiquitination may be a potential therapeutic strategy. ABSTRACT Non‐small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
Guangyao Zhou, Jiaxiong Tan, Pengpeng Zhang, Zhaokai Zhou, Lianmin Zhang, Zhenfa Zhang   +5 more
wiley   +1 more source